{"id":"W4200622882","doi":"10.3390/curroncol28060455","title":"Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; Ignyta; Genentech; Servier; Moderna; F. Hoffmann-La Roche; Incyte; Boston Pharmaceuticals; Adaptive Biotechnologies; Exelixis; Regeneron Pharmaceuticals; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Bevacizumab; Medicine; Renal cell carcinoma; Cancer research; Oncology; Interferon; Internal medicine; Nivolumab; Immunotherapy; Cancer; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00117633,0.001045944,0.002165655,0.0004111491,0.000301139,0.0008589505,0.0006092379,0.0009977825,0.001697787],"category_scores_gemma":[0.0007218685,0.0005031641,0.001355699,0.000410397,0.0004300372,0.0005516139,0.000284908,0.002325498,0.0005013996],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006601734,"about_ca_system_score_gemma":0.001506634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008439654,"about_ca_topic_score_gemma":0.002276873,"domain_scores_codex":[0.999721,0.0001253342,0.00002325958,0.00004342115,0.00002409359,0.00006295065],"domain_scores_gemma":[0.999519,0.00006697301,0.00008011691,0.00003250051,0.00004288509,0.0002585848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7112287,0.08370509,0.006059495,0.001463177,0.002194294,0.0003988259,0.0001749873,0.003003274,0.05328424,0.0003672512,0.003479904,0.1346407],"study_design_scores_gemma":[0.6359306,0.3518311,0.005417258,0.00005093114,0.0004720917,0.0002596656,0.00003018459,0.001178711,0.002394676,0.0001372978,0.002275082,0.00002244738],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845474,0.006037822,0.001015896,0.0005003116,0.0003634862,0.003827374,0.0006774979,0.0001143289,0.002915825],"genre_scores_gemma":[0.9855781,0.003715897,0.001961413,0.001159879,0.0002344046,0.003241891,0.00171891,0.00002405314,0.002365442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002165655,"threshold_uncertainty_score":0.006221116,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08100800184156026,"score_gpt":0.3767920522167323,"score_spread":0.2957840503751721,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}